Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RILPL1 (ImmuneEditome ID:353116)

1. Gene summary of enriched editing regions for RILPL1

Gene summary

Gene information	Gene symbol	RILPL1
	Gene ID	353116
	GeneSynonyms	GOSPEL\|OPDM4\|RLP1
	GeneCytomap	12q24.31
	GeneType	protein-coding
	GeneDescription	RILP-like protein 1\|GAPDH competitor of SIAH protein enhances life
	GeneModificationdate	20230404
	UniprotID	Q5EBL4;A0A1B0GVV3
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr12:123520293-123520562:-	ENST00000376874.7	ENSG00000188026.10	RILPL1	intronic	(AAAC)n,AluSx	chr12:123520293-123520562:-.alignment
chr12:123521820-123522888:-	ENST00000376874.7	ENSG00000188026.10	RILPL1	intronic	L2a,AluJr,L2b,AluSx1	chr12:123521820-123522888:-.alignment
chr12:123525001-123528168:-	ENST00000376874.7	ENSG00000188026.10	RILPL1	intronic	AluSz6,AluJo,AluJb,(CAAA)n,MLT1D,AluSx1,(AAAAT)n,MIR,L1MB7	chr12:123525001-123528168:-.alignment
chr12:123529360-123530262:-	ENST00000376874.7	ENSG00000188026.10	RILPL1	intronic	MER33,L2a,AluJo,AluSz6	chr12:123529360-123530262:-.alignment

Top

2. Tumor-specific enriched editing regions for RILPL1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000188026.10,RILPL1	BRCA	EAG	3.7755e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000188026.10,RILPL1	COAD	Path	EAG	3.6510e-02	9.7372e-03	0.3234

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for RILPL1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for RILPL1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000188026.10,RILPL1

ESCA

EAG

ENSG00000138382.9

chr2

169819560:169819643:169812456:169812524:169812456:169812506

0.2800

1.1956e-02

7.2566e-07

0.4850

ACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184

ENSG00000188026.10,RILPL1

ESCA

EAG

ENSG00000148399.7

chr9

137574751:137574843:137576079:137576167

0.3660

4.2754e-02

3.3355e-06

0.4007

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

Neutrophils

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000188026.10,RILPL1

UVM

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215792:77215844:77215909:77215935:77216023:77216036

-0.4700

3.8080e-02

2.6216e-04

-0.4290

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

ENSG00000188026.10,RILPL1

UVM

EAG

MEX

ENSG00000129657.10

chr17

77215740:77215753:77215792:77215818:77215818:77215935:77216023:77216036

-0.4518

4.9184e-02

2.9188e-04

-0.4290

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

More results

Top

5. Enriched editing regions and immune infiltration for RILPL1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000188026.10,RILPL1	ACC	EAG	Monocytes	1.4523e-02	0.5026
chr12:123520293-123520562:-	BRCA	EER	T_cells_regulatory_(Tregs)	2.3660e-02	0.3229
chr12:123521820-123522888:-	BRCA	EER	Dendritic_cells_activated	2.7382e-02	-0.3677
ENSG00000188026.10,RILPL1	BRCA	EAG	Neutrophils	4.9701e-02	0.0879
ENSG00000188026.10,RILPL1	CHOL	EAG	T_cells_gamma_delta	1.1868e-02	0.5152
ENSG00000188026.10,RILPL1	COAD	EAG	Dendritic_cells_activated	1.2951e-02	0.3361
chr12:123521820-123522888:-	ESCA	EER	Neutrophils	2.3212e-02	0.3206
ENSG00000188026.10,RILPL1	ESCA	EAG	T_cells_CD8	4.6228e-03	0.2498
ENSG00000188026.10,RILPL1	HNSC	EAG	Plasma_cells	2.2508e-03	0.2027
chr12:123521820-123522888:-	KIRC	EER	B_cells_memory	4.0233e-03	0.4346
ENSG00000188026.10,RILPL1	KIRC	EAG	Macrophages_M0	4.1748e-03	0.1903
chr12:123521820-123522888:-	KIRP	EER	Mast_cells_resting	1.4446e-02	0.4654
ENSG00000188026.10,RILPL1	KIRP	EAG	T_cells_CD4_memory_activated	4.2598e-02	0.1414
ENSG00000188026.10,RILPL1	LGG	EAG	B_cells_naive	4.0305e-02	0.2406
chr12:123521820-123522888:-	LUSC	EER	T_cells_regulatory_(Tregs)	1.9315e-02	0.3936
ENSG00000188026.10,RILPL1	LUSC	EAG	T_cells_follicular_helper	8.8647e-03	-0.1448
ENSG00000188026.10,RILPL1	MESO	EAG	Neutrophils	1.7765e-02	0.4164
ENSG00000188026.10,RILPL1	PRAD	EAG	Eosinophils	1.6320e-02	0.1509
ENSG00000188026.10,RILPL1	READ	EAG	T_cells_CD4_memory_activated	3.6836e-02	0.4474
ENSG00000188026.10,RILPL1	SKCM	EAG	T_cells_CD8	1.2657e-02	0.1315
ENSG00000188026.10,RILPL1	STAD	EAG	Plasma_cells	1.2365e-04	0.2637
ENSG00000188026.10,RILPL1	TGCT	EAG	Macrophages_M2	1.4172e-02	0.2458
chr12:123521820-123522888:-	THCA	EER	T_cells_CD4_memory_activated	1.2571e-04	0.7272
ENSG00000188026.10,RILPL1	UCS	EAG	Dendritic_cells_activated	7.7470e-04	0.5220

Top

6. Enriched editing regions and immune gene sets for RILPL1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000188026.10,RILPL1	BLCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	6.8561e-04	0.2204
chr12:123520293-123520562:-	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.4419e-04	0.5167
ENSG00000188026.10,RILPL1	BRCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.0887e-03	0.1458
chr12:123521820-123522888:-	BRCA	GSVA_HALLMARK_MYOGENESIS	EER	6.3070e-03	0.4467
ENSG00000188026.10,RILPL1	CESC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.0513e-02	0.2134
ENSG00000188026.10,RILPL1	CHOL	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.4172e-02	0.5041
ENSG00000188026.10,RILPL1	COAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.3692e-02	0.3075
ENSG00000188026.10,RILPL1	ESCA	GSVA_HALLMARK_E2F_TARGETS	EAG	9.4588e-03	-0.2295
ENSG00000188026.10,RILPL1	HNSC	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	2.9242e-02	0.1454
ENSG00000188026.10,RILPL1	KICH	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	3.5899e-02	-0.3509
ENSG00000188026.10,RILPL1	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	6.3479e-03	0.1814
ENSG00000188026.10,RILPL1	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.7892e-02	-0.1649
ENSG00000188026.10,RILPL1	LGG	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	2.1332e-02	0.2691
ENSG00000188026.10,RILPL1	LIHC	GSVA_HALLMARK_HEME_METABOLISM	EAG	7.4805e-03	-0.2916
chr12:123521820-123522888:-	LUAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	9.5381e-03	0.5396
ENSG00000188026.10,RILPL1	LUAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.2245e-02	0.1726
chr12:123521820-123522888:-	LUSC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	4.1987e-03	0.4720
ENSG00000188026.10,RILPL1	LUSC	GSVA_HALLMARK_APOPTOSIS	EAG	5.1948e-04	0.1912
ENSG00000188026.10,RILPL1	MESO	GSVA_HALLMARK_GLYCOLYSIS	EAG	8.1191e-03	0.4597
ENSG00000188026.10,RILPL1	OV	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.0081e-03	0.1933
ENSG00000188026.10,RILPL1	PAAD	GSVA_HALLMARK_P53_PATHWAY	EAG	4.8635e-02	-0.4066
ENSG00000188026.10,RILPL1	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.1497e-02	-0.1445
ENSG00000188026.10,RILPL1	READ	GSVA_HALLMARK_PEROXISOME	EAG	1.4710e-04	0.7223
ENSG00000188026.10,RILPL1	SARC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	4.3610e-03	0.3194
ENSG00000188026.10,RILPL1	SKCM	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	3.7492e-06	0.2413
ENSG00000188026.10,RILPL1	STAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	9.0942e-04	-0.2289
ENSG00000188026.10,RILPL1	TGCT	GSVA_HALLMARK_COAGULATION	EAG	3.9709e-07	0.4836
ENSG00000188026.10,RILPL1	THCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.6130e-03	0.1758
ENSG00000188026.10,RILPL1	THYM	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	3.0394e-02	0.3128
ENSG00000188026.10,RILPL1	UCEC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	4.4575e-04	0.3414
ENSG00000188026.10,RILPL1	UVM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	7.3430e-03	0.3224

Top

7. Enriched editing regions and drugs for RILPL1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000188026.10,RILPL1	ACC	GDC0941	EAG	2.2785e-03	-0.6039
ENSG00000188026.10,RILPL1	BLCA	Bicalutamide	EAG	9.7256e-03	-0.1687
ENSG00000188026.10,RILPL1	BRCA	A.770041	EAG	2.7969e-05	-0.1866
chr12:123521820-123522888:-	BRCA	GDC0941	EER	3.3161e-02	-0.3559
chr12:123520293-123520562:-	BRCA	LFM.A13	EER	3.1685e-02	0.3074
ENSG00000188026.10,RILPL1	CESC	CGP.082996	EAG	2.7695e-02	-0.1841
ENSG00000188026.10,RILPL1	ESCA	CEP.701	EAG	2.1917e-03	0.2694
ENSG00000188026.10,RILPL1	HNSC	AZD7762	EAG	1.2880e-02	0.1656
ENSG00000188026.10,RILPL1	KICH	LFM.A13	EAG	7.0162e-03	-0.4416
ENSG00000188026.10,RILPL1	KIRC	Gemcitabine	EAG	1.0949e-02	0.1693
chr12:123521820-123522888:-	KIRC	EHT.1864	EER	9.2431e-03	0.3970
ENSG00000188026.10,RILPL1	KIRP	Bryostatin.1	EAG	3.1575e-03	-0.2047
chr12:123521820-123522888:-	KIRP	Camptothecin	EER	2.1643e-02	0.4400
ENSG00000188026.10,RILPL1	LGG	Docetaxel	EAG	1.1716e-02	-0.2936
ENSG00000188026.10,RILPL1	LIHC	GDC.0449	EAG	3.7271e-02	-0.2290
chr12:123521820-123522888:-	LUAD	GNF.2	EER	5.4612e-04	-0.6765
ENSG00000188026.10,RILPL1	LUAD	AZD7762	EAG	6.8821e-03	-0.1860
chr12:123521820-123522888:-	LUSC	GDC0941	EER	3.8148e-04	-0.5671
ENSG00000188026.10,RILPL1	LUSC	A.770041	EAG	6.0925e-03	-0.1516
ENSG00000188026.10,RILPL1	MESO	JNK.9L	EAG	3.0846e-03	0.5067
ENSG00000188026.10,RILPL1	OV	JNJ.26854165	EAG	9.8002e-04	0.2207
ENSG00000188026.10,RILPL1	PAAD	BMS.708163	EAG	2.5696e-03	0.5869
ENSG00000188026.10,RILPL1	PRAD	ABT.888	EAG	7.7978e-03	0.1669
ENSG00000188026.10,RILPL1	READ	JNK.9L	EAG	5.4552e-03	0.5716
ENSG00000188026.10,RILPL1	SARC	FH535	EAG	5.6149e-03	0.3108
chr12:123521820-123522888:-	SKCM	CMK	EER	1.8079e-02	-0.4599
ENSG00000188026.10,RILPL1	SKCM	AZD.0530	EAG	2.5646e-05	-0.2202
chr12:123521820-123522888:-	STAD	BI.D1870	EER	3.4343e-03	0.5092
ENSG00000188026.10,RILPL1	STAD	BI.D1870	EAG	6.7678e-04	0.2344
ENSG00000188026.10,RILPL1	TGCT	AZD.0530	EAG	5.2905e-05	-0.3947
ENSG00000188026.10,RILPL1	THCA	BMS.708163	EAG	3.5732e-05	-0.2398
chr12:123521820-123522888:-	THCA	CI.1040	EER	1.4456e-02	-0.5137
ENSG00000188026.10,RILPL1	THYM	BI.2536	EAG	2.1978e-03	-0.4315
ENSG00000188026.10,RILPL1	UCEC	Axitinib	EAG	1.0679e-03	0.3194
ENSG00000188026.10,RILPL1	UCS	AP.24534	EAG	4.2870e-03	0.4530
ENSG00000188026.10,RILPL1	UVM	GSK269962A	EAG	6.2661e-03	-0.3283

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType